US · TEVA
Teva Pharmaceutical Industries Limited
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Tel Aviv 6944020
- Website
- tevapharm.com
Price · as of 2025-12-31
$34.95
Market cap 38.83B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $41.31 | +18.2% |
| Intrinsic Value(DCF) | $15.76 | -54.91% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $15.14 | -56.68% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $38.20 | $47.98 | $30.83 | $6.40 | $65.53 |
| 2012 | $35.09 | $44.96 | $1.25 | $1.03 | $41.99 |
| 2013 | $44.48 | $43.09 | $0.00 | $0.00 | $12.15 |
| 2014 | $55.51 | $60.15 | $3.53 | $3.33 | $28.43 |
| 2015 | $55.77 | $61.96 | $10.10 | $1.59 | $9.77 |
| 2016 | $32.61 | $68.47 | $10.33 | $0.00 | $6.56 |
| 2017 | $19.18 | $15.27 | $0.00 | $0.00 | $0.00 |
| 2018 | $15.75 | $29.63 | $0.00 | $0.00 | $14.71 |
| 2019 | $10.30 | $29.01 | $0.00 | $0.00 | $1.66 |
| 2020 | $10.79 | $23.98 | $0.00 | $0.00 | $0.00 |
| 2021 | $7.48 | $27.31 | $0.58 | $0.00 | $1.41 |
| 2022 | $9.12 | $23.88 | $0.00 | $0.00 | $0.00 |
| 2023 | $13.62 | $27.53 | $1.85 | $0.00 | $0.00 |
| 2024 | $15.36 | $26.86 | $0.00 | $0.00 | $0.00 |
| 2025 | $33.77 | $41.31 | $3.85 | $0.00 | $15.14 |
AI valuation
Our deep-learning model estimates Teva Pharmaceutical Industries Limited's (TEVA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $41.31
- Current price
- $34.95
- AI upside
- +18.2%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$15.76
-54.91% upside
Graham-Dodd
—
— upside
Graham Formula
$15.14
-56.68% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TEVA | Teva Pharmaceutical Indus… | $34.95 | 38.83B | +18% | -55% | — | -57% | 27.36 | 4.91 | 2.25 | 16.76 | — | -3.27 | 51.79% | 12.50% | 8.17% | 21.35% | 10.30% | 3.54% | 2.20 | 2.35 | 1.04 | 0.54 | 4.40 | -18276.00% | 431.00% | 5327.00% | 2.96% | 0.12 | 5.48% | 0.00% | 0.00% | 2.46% | 24.40 | 45.84 | 3.05 | 0.85 |
| BIIB | Biogen Inc. | $191.82 | 28.15B | +13% | -50% | -35% | -56% | 21.34 | 1.51 | 2.81 | 9.91 | — | 10.66 | 70.47% | 19.14% | 13.18% | 7.39% | 8.18% | 4.50% | 0.38 | 7.63 | 2.68 | 1.70 | 1.27 | -2109.00% | 139.00% | -1848.00% | 7.43% | 0.66 | 9.68% | 0.00% | 0.00% | 1.14% | 16.36 | 14.98 | 3.13 | 3.23 |
| BNTX | BioNTech SE | $110.23 | 26.51B | +25% | -21% | -31% | -45% | -32.97 | 1.15 | 8.12 | -15.84 | — | 1.23 | 80.32% | -47.77% | -24.18% | -3.42% | -37.96% | -2.98% | 0.01 | -99.86 | 7.45 | 7.26 | 25.90 | -17232.00% | -2796.00% | -10524.00% | -1.09% | 0.08 | -7.20% | 0.00% | 0.00% | 0.00% | -4.42 | -23.77 | 2.11 | 6.28 |
| DXCM | DexCom, Inc. | $73.43 | 28.64B | +15% | -6% | -76% | -33% | 34.42 | 10.48 | 6.18 | 24.22 | 72.96 | 10.86 | 60.10% | 19.56% | 17.94% | 34.50% | 32.99% | 13.04% | 0.51 | — | 1.88 | 1.53 | 0.41 | 4718.00% | 1560.00% | 7079.00% | 3.74% | 0.67 | 50.72% | 0.00% | 0.00% | 6.98% | 30.91 | 26.16 | 6.04 | 6.91 |
| LH | Labcorp Holdings Inc. | $289.12 | 23.97B | -28% | -60% | -89% | -45% | 27.16 | 2.77 | 1.71 | 15.16 | 148.18 | -13.50 | 26.75% | 10.87% | 6.28% | 10.53% | 8.26% | 4.77% | 0.84 | 6.77 | 1.42 | 0.99 | 3.31 | 1833.00% | 725.00% | 1005.00% | 5.06% | 0.58 | 8.29% | 1.01% | 27.40% | 2.90% | 20.12 | 25.30 | 2.19 | 3.23 |
| NBIX | Neurocrine Biosciences, I… | $132.25 | 13.27B | +32% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| NTRA | Natera, Inc. | $208.04 | 29.01B | -52% | +773% | -99% | — | -92.12 | 14.68 | 10.34 | -113.19 | — | 14.68 | 60.30% | -13.10% | -11.22% | -19.42% | -59.87% | -12.28% | 0.16 | -20.80 | 4.00 | 3.73 | 5.12 | -5952.00% | 5675.00% | -12420.00% | 0.39% | 0.39 | 18.65% | 0.00% | 0.00% | 3.18% | -75.40 | 242.08 | 9.88 | 21.78 |
| PHG | Koninklijke Philips N.V. | $32.00 | 30.68B | +25% | -54% | -95% | -76% | 28.63 | 2.34 | 1.44 | 11.71 | — | -29.02 | 45.18% | 7.98% | 5.02% | 7.80% | 6.50% | 3.20% | 0.74 | 4.28 | 1.32 | 0.84 | 2.00 | -22400.00% | -104.00% | -3406.00% | 3.49% | 0.15 | 5.36% | 1.28% | 36.60% | 1.28% | 21.71 | 34.62 | 1.73 | 2.09 |
| PODD | Insulet Corporation | $246.61 | 17.36B | -11% | +250% | -84% | -46% | 69.88 | 11.40 | 6.38 | 29.99 | — | 12.82 | 71.63% | 17.50% | 9.12% | 18.12% | 19.54% | 7.87% | 0.69 | 5.94 | 2.78 | 1.81 | 0.57 | -3979.00% | 3073.00% | 2367.00% | 2.19% | 0.84 | 21.40% | 0.00% | 0.00% | 1.12% | 37.15 | 46.60 | 6.50 | 8.10 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
- CEO
- Richard D. Francis
- Employees
- 37K
- Beta
- 0.72
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($15.76 ÷ $34.95) − 1 = -54.91% (DCF, example).